ABSTRACT
There have not been many new developments in topical therapies for psoriasis in the past few years. One of the few new topical agents that was recently approved by the United States Food and Drug Administration is a fixeddose formulation of 0.064% betamethasone dipropionate and 0.005% calcipotriene ointment (Taclonex). This fixed-dose combination therapy is discussed separately in Chapter 7. In this chapter, we will discuss other new topical psoriatic therapies including a new spray formulation of clobetasol propionate 0.05% (Clobex Spray) and two other formulations of clobetasol propionate 0.05%, a shampoo (Clobex Shampoo), and lotion (Clobex Lotion) as well as Hydrogel patch.
